Introduction
ExosomeDx is a non-invasive urine test that evaluates biomarkers associated with prostate cancer. It is particularly valuable for patients at risk for prostate cancer, helping to determine the need for a prostate biopsy. At Crossroads Urology, ExosomeDx testing is part of our comprehensive approach to prostate cancer detection and management.
Purpose
ExosomeDx testing is used to:
- Assess the risk of high-grade prostate cancer in men with elevated PSA levels.
- Help determine whether a prostate biopsy is necessary.
- Reduce unnecessary biopsies and associated complications.
- Monitor patients with low-risk prostate cancer on active surveillance.
Procedure
- Patients provide a urine sample after a digital rectal exam (DRE) to ensure the collection of prostate-derived exosomes.
- The sample is sent to the laboratory, where exosomal RNA biomarkers are analyzed to calculate a risk score.
- Results are typically available within 7-10 days.
Preparation
- Patients should avoid ejaculation for at least 48 hours before the test to improve accuracy.
- Inform the provider of any medications or supplements that may affect PSA levels, such as finasteride.
Risks and Considerations
- The test is non-invasive and carries no risks.
- Results should be interpreted alongside PSA levels, imaging, and clinical findings for a comprehensive evaluation.
At Crossroads Urology, we integrate ExosomeDx testing into our diagnostic process to ensure informed decision-making and personalized care.
Results
- Results provide a risk score that stratifies patients into low, intermediate, or high risk for high-grade prostate cancer.
- A high-risk score may prompt further evaluation, such as MRI or prostate biopsy.
Conclusion
ExosomeDx offers a cutting-edge, non-invasive approach to prostate cancer risk assessment. At Crossroads Urology, we utilize advanced diagnostics like ExosomeDx to provide accurate, patient-focused care. Contact us today to learn more about ExosomeDx testing and schedule your evaluation.
